About 100 reports

  • BLOOD DISEASE DRUGS
  • Blood Disease Drugs Industry Structure

This study focuses on China’s Blood Disease Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China...

  • Blood Disease
  • China
  • Eisai Co., Ltd.
  • Roche Pharmaceutical Co., Ltd
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • BLOOD DISEASE DRUGS
  • Blood Disease Drugs Sales Volume

China’s demand for Blood Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...

  • Blood Disease
  • China
  • Demand
  • Eisai Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Other Blood Disease Drugs
  • Blood Disease Drugs Imports

This study focuses on China’s Blood Disease Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s...

  • Blood Disease
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Offices of physicians nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand

The report features 2017 current and 2018 forecast estimates on the sales of Patient care - Blood diseases sold through Medical & surgical hospitals nationally and for all ## U. S.

  • Blood Disease
  • Pathology
  • United States
  • Demand
  • Global Acquired Orphan Blood Diseases Therapeutics Market
  • Global Acquired Orphan Blood Diseases Therapeutics Market

About Acquired Orphan Blood Diseases Therapeutics Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can...

  • Blood Disease
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • The content of this press release is solely the views of its authors and does not represent the official views of the National Institutes of Health.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017 Summary According to the recently published report ’Hepcidin - Pipeline Review, H2 2017’; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target...

  • Blood Disease
  • Turkey
  • United States
  • World
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

Polycythemia Vera - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape. Polycythemia Vera (PV) is a stem...

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012

Polycythemia Vera - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape. Polycythemia Vera (PV) is a stem...

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative

Additional Areas in Sickle Cell Disease Date and Time: Thursday, October ##, 2017, ##:##-##:## p. m.

  • Blood Disease
  • Healthcare
  • Pharmaceutical
  • Therapy
  • World
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

Fanconi Anemia - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Pipeline Review, H2 2017, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape. Fanconi anemia (fan-KO-nee...

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • Hematology Drugs Market Historic Growth

Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases.

  • Blood Disease
  • World
  • Bayer AG
  • Novo Nordisk Group
  • Shire plc
  • BIOMARKER ASSAY - SEPSIS - PRODUCT DESCRIPTION

Liquid biopsy: Detection of cancer or other diseases by testing bodily fluids such as blood.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • Medical Device
  • Grifols, S.A.
  • DIAGNOSTIC TEST - HEMOPHILIA - PRODUCT DESCRIPTION
  • RAPID QUANTITATIVE HEPARIN-INDUCED THROMBOCYTOPENIA (H.I.T.) TEST - PRODUCT DESCRIPTION

From ## of these players, blood samples were taken ##, ##, ## and ## hours (six days) after the concussion.

  • Blood Disease
  • Clinical Trial
  • In Vitro Diagnostics
  • Point Of Care Testing
  • Siemens Healthcare GmbH
  • Dec 04, 2017: La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC-401 in Patients With Beta Thalassemia
  • SMALL MOLECULES TO INHIBIT PRMT5 FOR HAEMOGLOBINOPATHIES AND SOLID TUMOURS - DRUG PROFILE

VCN in peripheral blood was ##. ##copies/ genome at ## month after LentiGlobin infusion.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation

PV and ET, along with myelofibrosis (MF), are blood cancers that belong to a group of diseases known as myeloproliferative neoplasms (MPNs).

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - Drug Profile

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H1 2017 Summary Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation...

  • Blood Disease
  • Therapy
  • Turkey
  • United States
  • Product Initiative

BY SEX, 2012 (NO. ) ## Hodgkin Lymphoma in the United Kingdom ## TABLE ## ESTIMATED NUMBER OF NEW CASES OF HODGKIN LYMPHOMA IN THE U. K., 2013 (NO. ) ## TABLE ## ESTIMATED NUMBER OF DEATHS FROM HODGKIN' S LYMPHOMA IN THE U. K., 2012 (NO. ) ## FIGURE ## ESTIMATED NUMBE

  • Blood Disease
  • Cancer
  • Pathology
  • United States
  • World
  • 10. Key Contacts Capacity
  • 11. General News, Project News

Synopsis "NIBD – Blood Disorder Hospital Development – Sindh - Project Profile" contains information on the scope of the project including project overview and location. The profile also details project ownership and funding, gives a full project description, as well as information on contracts, tendering and key project...

  • Blood Disease
  • Construction
  • Hospital
  • Pathology
  • World
  • Market challenges

Males are susceptible to this disease as they have only one X chromosome.

  • Blood Disease
  • World
  • Market Size
  • Biogen Idec Inc.
  • CSL Behring GmbH
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

Fanconi Anemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Pipeline Review, H1 2018, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape. Fanconi anemia (fan-KO-nee...

  • Blood Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • MEXICO: APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021 (USD MILLION)
  • GLOBAL THERAPEUTIC APHERESIS MARKET SIZE, BY PROCEDURE, 2014-2021, (USD MILLION)

S. ##. ##. ##. ## The FDA approves apheresis blood collection devices intended for the collection of certain blood components only.

  • Blood Disease
  • North America
  • United States
  • World
  • Market Size

Enrollment and treatment are ongoing in Part ## of the Phase ## trial in patients with CMT disease.

  • Blood Disease
  • United States
  • World
  • Company
  • Acceleron Pharma, Inc.

PT/ ##:## p. m.

  • Blood Disease
  • Clinical Trial
  • Point Of Care Testing
  • Rapid Test
  • Helena Laboratories Corporation
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones

In addition, treatment with ACE-## corrected anemia in animal models of chronic kidney disease and acute blood loss.

  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Acceleron Pharma, Inc.
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • Vaccine
  • United States
  • Merck & Co., Inc.
  • RECENT DEVELOPMENTS IN BLOOD DISORDERS BIOSIMILARS
  • GLOBAL - BLOOD DISORDERS BIOSIMILARS MARKET (MILLION US$), 2014 - 2015

The application of biosimilars in blood disease treatment is one of the highest revenue generating segment owing to the high-priced reference biologics and frequent application.

  • Blood Disease
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • CLINICAL TRIAL PROFILE SNAPSHOTS

One anti-drug antibody was observed for ALXN## and one for Soliris.

  • Blood Disease
  • Leukemia
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.
  • BIOMARKER ASSAY - POLYCYTHEMIA VERA - PRODUCT DESCRIPTION
  • EON 100 AUTOMATED CHEMISTRY ANALYZER - UIBC ASSAY - PRODUCT DESCRIPTION

THE FREQUENCY OF HEALTHY CARRIERS OF THIS DISEASE IN THE GENERAL POPULATION IS ##/ ## TO ##/ ##.

  • Blood Disease
  • Clinical Trial
  • Hospital
  • Nucleic Acid
  • GlobalData's company
  • Clinical Trial profile. 229 Trial Title
  • 5. All the trials included are unique trials.

Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions GDCT## NCT##, CICL##A## Hematological Disorders Anemia, Sickle Cell Disease (Creatinine, Protein/ Creatinine) Completed Phase II Interventional deferasirox ODT Novar

  • Blood Disease
  • Clinical Trial
  • World
  • Product Initiative
  • Novartis AG